Hair Loss

L’Oréal patents methods for the prognosis, diagnosis and treatment of hair loss for alopecia

L'Oréal patents methods for the prognosis, diagnosis and treatment of hair loss for alopecia

Write in his international patent​, L’Oréal said it has developed a method to in vitrothe prognosis and/or diagnosis of a “common alopecic condition of the scalp”​ by measuring the level of expression of very specific genes* involved in the intercellular junctions of the scalp and/or the hair follicle. He also described a in vitro​ method to assess the effectiveness of treating a common alopecic condition, including testing cosmetic treatments such as hair lotions, gels, shampoos and conditioners made using gene modulator and certain active compounds.

*Genes identified by L’Oréal: CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MY03B, MY05B, MY06, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN8, CLDN10, CLDN19, and possibly CTNNB1 and CTNND2

L’Oréal has indicated the prognosis, diagnosis and methods of treatment specifically related to common alopecia caused by disturbances of the hair cycle, as opposed to immune alopecia such as alopecia areata or localized baldness, universal alopecia areata and total alopecia areata. Evaluation and treatment could therefore be used for the likes of androgenetic alopecia, traction alopecia, hair loss in women, cicatricial alopecia, chemotherapy-induced alopecia or radiation therapy, telogen effluvium, stress-related alopecia, seasonal alopecia, age-related alopecia and micro-inflammatory alopecia.

Understanding Substantial Temporary or Permanent Hair Loss

“Natural hair loss can be estimated, on average, at a few hundred hairs per day for a normal physiological state”,the company wrote in its patent filing. “This process of constant physical renewal undergoes a natural evolution during aging: the hair becomes thinner and its cycles shorter. Various causes can, however, lead to significant hair loss, whether temporary or permanent,”L’Oréal wrote in its patent filing.